Abstract 784P
Background
The incidence of HPV integration is increased during the disease progression from precancerous lesions to carcinoma, and HPV integration is reputed as a key effect to escape eliminations from the host cells. Although HPV integration is identified in HPV-related carcinoma, the mechanisms underlying HPV carcinogenesis remain unclear.
Methods
Here, 6768 HPV integration sites from cervical carcinoma (CESC) and 470 from head & neck carcinoma (HNSC), high-through chromosome conformation capture (Hi-C), ChIP-seq, ChIP-PCR and RNA-seq were analyzed to identify the HPV integration characteristics in HPV-host interactions. Manual HPV-integration cells, an HPV integration mouse model (K14-HPV, FVB/N), and CRISPR-Cas9 knock-out cells were performed to demonstrate the chromatin remolding between universal stripe factors (USFs) and super-enhancers.
Results
In CESC and HNSC, USF motifs were enriched in HPV integration sites and integrated HPV-host interaction regions. In addition, HPV integration sites and integrated HPV-host interaction regions marked increased chromatin accessibility (ATAC-seq) and super-enhancer elements (H3K27ac, H3K4me1, and H3K4me3), with USF motifs enrichment in these regions. By dividing the tumor samples according to HPV status, USF genes were found to be upregulated in CESC and HNSC, which could be validated by tumor samples, manual HPV-integration cells, and the K14-HPV integration mouse model. Furthermore, three-dimensional chromatin analyses reveal the chromatin interactions between USF genes and super enhancers in tumor cells. The expression patterns of USF genes and chromatin interactions between USF genes and the super-enhancer were reversed via super-enhancer CRISPR-Cas9 knock-out, thus reversing malignant phenotypes of tumor cells in vitro and in vivo.
Conclusions
Overall, we identify that HPV integration remodels chromatin interactions between USFs and super enhancers to promote malignant phenotypes in HPV-related carcinoma, which provides insight into the three-dimensional mechanism in HPV-related carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. CAO.
Funding
National Key R&D Program of China (21YFC2701201) and the National Natural Science Foundation of China (82072895, 82141106, and 82203453).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11